All News

FDA warns of adverse effects with buccal fentanyl use.

The Senate passed legislation delaying implementation of the Medicaid rule mandating tamper-resistant Rx pads and awaits House action.

Generic versions of Marinol should be classified as Schedule III when they are approved, according to the Drug Enforcement Administration

Medicare keeping limits on anemia drugs

Genetic differences predict anti-inflammatory benefits from nutritional products

Shop 'n Save Pharmacy to provide Vitality Check wellness service

NACDS Foundation Chain Pharmacy Industry Profile highlights role of pharmacists

College of Pharmacy gets new home

NACDS debunks New York Times article, "The 'Poisonous Cocktail' of Multiple Drugs"

Oripavine is designated a Schedule II controlled substance by the Drug Enforcement Administration

National Quality Forum releases standards for substance abuse treatment

New on-line tool for calculating pain medication index

TWC Global issues recall of Axcil and Desirin

NCCN updates its dermatofibrosarcoma protuberans guidelines.

NCCN updates hepatobiliary cancer treatment guidelines.

ASHP launches on-line resource center

CMS outlines plans for contacting low-income subsidy beneficiaries for Medicare Part D program.

CVS/pharmacy to offer flu vaccinations in over 4,000 stores.

FDA warns about risk of Cryptosporidium illness from Baby's Bliss Gripe Water

Pharmacy owner pleads guilty to charges stemming from Affpower Internet pharmacy.

Hospitals swallowing cost of errors

Campath granted regular approval

New study results released for once-yearly Reclast (zoledronic acid) injection

Valeant Pharmaceuticals offers zelaCARD rebate program to Parkinson's disease patients.

Americans confident about drug safety

Personalized medicine report issued by HHS

Study from AHRQ and FDA will examine cardiovascular risks of ADHD drugs.

A PhRMA-sponsored study claims Medicare Part D reduced expenses for beneficiaries who had no insurance prior to the program.